ResearchPoint, Azaya Initiate Enrollment In Phase I ATI-1123 Trial
The company said that ATI-1123 has the same active ingredient as the FDA approved drug, Taxotere (docetaxel). The study is being conducted at two premier Texas cancer centers,
Novartis has entered a collaboration with Chai Discovery to advance the use of AI in the identification of therapeutic antibodies.